DocMorris

The Karlsruhe regional court will decide on December 9 on the fundamental lawfulness of dm-med’s business model. The dispute is whether dm-med is sufficiently separated from the dm drugstore chain and clearly identifiable as an independent mail-order pharmacy. A victory for the Wettbewerbszentrale could reduce competitive pressure on online pharmacies like DocMorris; dm-med currently sells only pharmacy-only but non-prescription medicines. The announcement weighed on DocMorris shares, which fell significantly intraday at times. » Plus sur finanzen.net

DocMorris has set the final terms for the newly issued convertible bond maturing in 2031: the conversion price is CHF 13.83 per share (conversion premium 32.5% versus the reference price of CHF 10.4374). The issue volume is CHF 96.8 million and was significantly oversubscribed by institutional investors. The maturity was extended from 2028 to 2031, the coupon was cut from 3.0% to 1.5%, and the number of underlying shares was reduced from 7.6 million to 7.0 million. The proceeds are intended for general corporate purposes. » Plus sur finanzen.net

DocMorris has successfully completed a privately placed convertible bond maturing in 2031. The volume is around CHF 100 million with a coupon of 1.5% and a conversion premium of 32.5% versus the reference price. The proceeds will be used to repurchase the 2028 convertible bond and for general corporate purposes, thereby extending the maturity profile to 2031. The number of underlying shares for the outstanding 2028 convertibles has been reduced from 7.6 million to 7.0 million. » Plus sur finanzen.net